20 studies found for:    istradefylline
Show Display Options
Rank Status Study
1 Recruiting A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease
Condition: Idiopathic Parkinson's Disease
Interventions: Drug: Istradefylline 40 mg;   Drug: Istradefylline 20 mg;   Drug: Placebo
2 Completed A Phase 2b Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa
Condition: Parkinson's Disease
Interventions: Drug: Istradefylline;   Drug: Placebo
3 Completed Study of KW-6002 (Istradefylline) for the Treatment of Parkinson's Disease in Patients Taking Levodopa
Condition: Parkinson's Disease
Interventions: Drug: Istradefylline;   Drug: Placebo
4 Recruiting The Effect of Rifampin on the Metabolism of Istradefylline in Healthy Volunteers.
Condition: Study of the Effect of a Strong CYP3A4 Inducer on the Pharmacokinetics of Istradefylline
Interventions: Drug: Istradefylline;   Drug: Rifampin
5 Completed A Study of Istradefylline (KW-6002) in Treating Patients With Parkinson's Disease on Levodopa
Condition: Parkinson's Disease
Intervention: Drug: Istradefylline (KW-6002)
6 Completed A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease
Condition: Parkinson's Disease
Intervention: Drug: Istradefylline (KW-6002)
7 Completed A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa
Condition: Parkinson's Disease
Intervention: Drug: Istradefylline (KW-6002)
8 Completed A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa
Condition: Parkinson's Disease
Intervention: Drug: Istradefylline (KW-6002)
9 Completed Long-Term Safety Study of KW-6002 (Istradefylline) in Parkinson's Disease Patients
Condition: Parkinson's Disease
Intervention: Drug: Istradefylline
10 Terminated
Has Results
An Extension of Istradefylline in North American Parkinson's Disease Patients Who Have Completed Study 6002-INT-001
Condition: Parkinson's Disease
Intervention: Drug: Istradefylline
11 Completed A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease
Condition: Parkinson's Disease
Intervention: Drug: Istradefylline (KW-6002)
12 Completed Study of KW-6002 (Istradefylline) in Parkinson's Disease in Patients With Motor Response Complications on Levodopa
Condition: Parkinson's Disease
Intervention: Drug: Istradefylline
13 Completed Study of Istradefylline (KW-6002) for the Treatment of Restless Legs Syndrome
Conditions: Sleep Disorder;   Restless Legs Syndrome
Intervention: Drug: Istradefylline (KW-6002)
14 Completed A Study of Istradefylline (KW-6002) as Monotherapy in Parkinson's Disease (PD) Patients
Conditions: Parkinson's Disease;   Movement Disorder Syndrome
Intervention: Drug: Istradefylline (KW-6002)
15 Completed 12-Week, Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy of 40 mg/Day KW-6002 in Parkinson's Disease Patients on Levodopa/Carbidopa
Condition: Parkinson's Disease
Intervention: Drug: KW-6002 (istradefylline)
16 Completed An Extension of Istradefylline in Parkinson's Disease Patients Who Have Completed Studies 6002-EU-007, 6002-US-013 or 6002-US-018
Condition: Parkinson's Disease
Intervention: Drug: Istradefylline ( KW-6002)
17 Completed A Long-Term, Safety Study With a Flexible Dose Range of KW-6002 in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy
Condition: Parkinson's Disease
Intervention: Drug: istradefylline
18 Completed 12-Week, Double-Blind, Placeob-Controlled Study of 20 and 60 mg/Day Istradefylline in Parkinson's Disease Patients on Levodopa/Carbodopa
Condition: Parkinson's Disease
Intervention: Drug: Istradefylline (KW-6002)
19 Completed KW-6002 to Treat Parkinson's Disease
Condition: Parkinson's Disease
Interventions: Drug: KW-6002;   Drug: IV Levodopa
20 Recruiting Observational Study for Non-motor Symptoms and Treatment in Parkinson's Disease Patients
Condition: Parkinson Disease
Intervention:

Indicates status has not been verified in more than two years